文献速递前列腺增生与排尿功能障碍

BPH术后启动储尿期LUTS药物治疗的累积发生率与相关因素

Initiation of Medical Therapy for Storage Lower Urinary Tract Symptoms After Benign Prostatic Hyperplasia Surgery.
PubMed 文献 · J Urol · 2026-10-22

基于密歇根州2017-2022年理赔数据,纳入11,519例BPH术前未使用抗胆碱能或β3激动剂的患者,评估术后3-12个月启动该类药物的累积发生率。12个月累积发生率为5.7%(TUMT)至11%(PVP),PVP较TURP启动风险更高(HR 1.49,95%CI 1.25-1.79)。

要点

  • BPH术后启动抗胆碱能/β3激动剂不常见,但12个月累积发生率因术式而异,为5.7%-11%。
  • PVP较TURP与更高的药物启动风险相关(HR 1.49,95%CI 1.25-1.79)。
  • 既往BPH药物使用和抗凝使用与更高启动风险相关,术前留置尿管与更低风险相关。

核心结论

  • 在未使用抗胆碱能/β3激动剂的BPH手术患者中,术后启动该类药物治疗不常见但存在术式差异,PVP风险最高。

研究设计与样本

  • 基于密歇根州2017-2022年理赔数据的回顾性队列研究,纳入11,519例BPH术前未使用抗胆碱能/β3激动剂的患者,比较九种BPH术式。

主要发现

  • 术后12个月启动抗胆碱能/β3激动剂的累积发生率为5.7%(TUMT)至11%(PVP)。
  • 多变量分析中,PVP较TURP与更高的启动风险相关(HR 1.49,95%CI 1.25-1.79)。
  • 既往BPH药物使用和既往抗凝使用与更高启动风险相关,术前留置尿管依赖与更低风险相关。

临床怎么用

  • 咨询BPH术式选择时,可参考术式特异的12个月药物启动累积发生率(5.7%-11%)。
  • 对PVP患者应关注术后储尿期症状,必要时启动抗胆碱能/β3激动剂治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: De-novo anticholinergic or beta-3 agonist (Ach/B3a) initiation for storage lower urinary tract symptoms (LUTS) is a clinically significant but understudied outcome after benign prostatic hyperplasia (BPH) surgery. We estimated procedure-specific cumulative incidence of Ach/B3a medication initiation and identified associated patient- and procedure-level factors. MATERIALS AND METHODS: Using Michigan statewide claims data (2017-2022) from the Michigan Value Collaborative, Ach/B3a-naive patients who underwent BPH surgery were identified. Procedures included transurethral resection of the prostate (TURP), laser photovaporization (PVP), laser enucleation of the prostate (LEP), robotic waterjet therapy (RWJT), prostatic urethral lift (PUL), water vapor thermal therapy (WVTT), transurethral microwave thermotherapy (TUMT), prostatic artery embolization (PAE), and simple prostatectomy (SP). De-novo Ach/B3a initiation was defined as a prescription fill for an Ach/B3a between 3 and 12 months postoperatively. Cumulative incidence was estimated by Kaplan-Meier analysis; Cox proportional hazards models identified associated factors. RESULTS: The cohort comprised 11,519 Ach/B3a medication-naive patients. Twelve-month cumulative incidence ranged from 5.7% (TUMT) to 11% (PVP). On multivariable analysis, PVP was associated with higher hazard of initiation compared to TURP (HR 1.49, 95% CI 1.25-1.79). Prior BPH medication use, and prior anticoagulation use were associated with higher hazard of initiation, while preoperative catheter dependence was associated with lower hazard. CONCLUSIONS: In this statewide cohort of Anticholinergic and Beta-3 agonist naive patients undergoing contemporary BPH procedures, de-novo Ach/B3a medication initiation was uncommon but procedure-specific, with 12-month cumulative incidence ranging from 5.7% - 11%, with PVP carrying the highest hazard. These findings provide real-world benchmarks to guide counseling across contemporary BPH interventions.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Uy M, DiBianco JM, Mansour S, et al. Initiation of Medical Therapy for Storage Lower Urinary Tract Symptoms After Benign Prostatic Hyperplasia Surgery. J Urol. 2026. PMID: 42912966. doi:10.1097/JU.0000000000005352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。